David Rimm, MD, PhD
Anthony N. Brady Professor of Pathology and Professor of Medicine (Medical Oncology)Cards
About
Research
Overview
Nearly 100% of Dr. Rimm’s lab efforts are related to cancer. He has largely focused on tissue biomarker research. His most innovative research has involved construction of patient cohorts using the tissue microarray format and the development of methods for quantitative analysis of protein expression on tissue microarrays and whole tissue sections. He has also published extensively in the field of biospecimen science including a series of papers published in Laboratory Investigation, the most popular being cited over 1000 times[2]. His most innovative efforts have been related to automated quantitative analysis of formalin fixed, paraffin embedded tissue.
He and his lab developed the AQUA method of quantitative immunofluorescence that was published in 2002 in Nature Medicine (over 875 citations). This technology attempted to remove the subjectivity from the analysis of immunohistochemistry specimens by using co-localization to define regions of interest, rather than feature extraction of pathologist defined subregions.
More recently, he has extended the quantitative work toward the development of standardized assay for antibody drug conjugate therapies (ADCs).
Medical Subject Headings (MeSH)
Academic Achievements and Community Involvement
Clinical Care
Overview
David L. Rimm, MD, PhD, is a pathologist who specializes in biomarker assessment in lung and breast cancer and has dedicated much of his career to improving how cancers can be diagnosed through better diagnostic tests or through discovering new molecular biomarkers. As a medical student, Dr. Rimm so enjoyed puzzling over the origins and process of diagnosing a patient’s disease that a mentor suggested he consider specializing in pathology. “It always seemed like the most scientific area of medicine, where you have time to perform research to improve diagnostics for patients,” Dr. Rimm says.
His natural inclination toward research pushed Dr. Rimm to sub-specialize in cytopathology, a branch of pathology where diagnoses are based on examining very small samples of patient’s tissue at a cellular level.
Clinical Specialties
Board Certifications
Cytopathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 1996
Anatomic Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 1995
Yale Medicine News
Links & Media
News
- August 29, 2024
YCC Publications 2024
- July 09, 2024
Immunotherapy for NSCLC: Potential Biomarkers for Resistance Are Identified
- June 26, 2024
Yale Study Finds Potential in Predicting Immunotherapy Outcomes in Patients with Melanoma
- June 26, 2024Source: OncLive
Dr. Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer